Mounjaro (Tirzepatide) Thailand

Mounjaro (Tirzepatide) is an injectable prescription medication that has been approved by the U.S. FDA for inclusion in its indications for obesity. 

Tirzepatide is a dual receptor agonist that acts on both GIP and GLP-1, helping to reduce appetite, slow gastric emptying, and thereby aid in weight loss and weight management. 

With its dual action on blood sugar and appetite regulation, Mounjaro has garnered significant attention in recent years as a potential option for weight loss assistance.

The mechanism of action of Mounjaro (Tirzepatide) involves its active ingredient, Tirzepatide, which can simultaneously act on both GIP and GLP-1 intestinal hormone receptors, resulting in multiple metabolic benefits:

• Regulating Blood Sugar: By reducing hunger and controlling appetite.

• Appetite Control: By suppressing hunger, making it easier to avoid overeating.

• Enhancing Satiety: By slowing gastric emptying, prolonging the feeling of fullness.

• Optimizing Energy Metabolism: By promoting the regulation and utilization of energy by the brain and fat cells, aiding in weight management.

Who is suitable for using Mounjaro (Tirzepatide)?

Mounjaro is suitable for the following two categories of adult populations:

• Those with a Body Mass Index (BMI) of 30 or above (meeting the criteria for obesity);

• Individuals with a BMI between 27 and 29.9 who also have at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia.

This medication, by activating both the GIP and GLP-1 receptors, not only stimulates insulin secretion but also helps regulate appetite, reduce food intake, and enhance satiety, providing a comprehensive approach to weight control.

Not Recommended for Users:

If you have a history of medullary thyroid carcinoma, a family history of the condition, multiple endocrine neoplasia type 2 (MEN 2), or a history of pancreatitis, it is advised to avoid using Mounjaro and consult a doctor.

Differences Between Mounjaro and Other Weight Loss Medications:

While most weight loss medications on the market primarily target the GLP-1 receptor, Mounjaro simultaneously stimulates the GIP and GLP-1 dual pathways. This breakthrough mechanism has shown more significant weight loss effects in clinical trials.

Studies have indicated that some users may experience weight reductions of up to 20%, surpassing the effects of single-receptor drugs. However, the actual efficacy still depends on individual physiology and lifestyle.

Dosage and Administration:

Mounjaro is a subcutaneous injection medication administered once weekly. It can be injected into the abdomen, thigh, or upper arm, and does not need to be synchronized with meal times. The recommended dosage adjustment is as follows:

• Weeks 1-4: Inject 2.5 milligrams weekly

• Week 5 and beyond: Increase to 5 milligrams weekly

• Further adjustment: If additional blood sugar control is needed, after at least 4 weeks at the current dosage, increase by 2.5 milligrams each time, up to a maximum of 15 milligrams weekly.

Please note: Dosage adjustments should be evaluated and instructed by a physician. Do not self-adjust the dosage or change the administration method.

Mounjaro Side Effects:

During the use of Mounjaro, some individuals may experience gastrointestinal discomfort. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion, and abdominal pain. These reactions are typically mild to moderate and tend to gradually alleviate with continued use.

However, in rare cases, more severe side effects may occur, such as pancreatitis, gallbladder issues, renal dysfunction, and even a potential risk of thyroid tumors. It is recommended to closely monitor changes in the body during use. If severe abdominal pain, persistent vomiting, or other abnormal symptoms occur, discontinue the medication immediately and seek medical assistance.

Precautions Before Using Mounjaro:

1. Long-term Medical Monitoring Required: Mounjaro is suitable for long-term weight management, but like all prescription medications, long-term use may still pose risks. Users should schedule regular follow-up appointments for the physician to assess effectiveness and overall health status and address any potential issues promptly.

2. Avoid Concomitant Use with Other GLP-1 Agonists: Do not combine Mounjaro with other GLP-1 receptor agonists to prevent drug interactions. Before use, proactively inform your physician about any prescription medications, over-the-counter drugs, or dietary supplements you are currently taking to enable the physician to make the most appropriate judgment.

*The information in this text is for reference only. Actual dosage and timing of medication should be directed by a doctor and used correctly according to the product manual.

Handling and Storage Instructions:

Unused Pen:

• Store unused pens in a refrigerator at 2°C to 8°C.

• If kept in the refrigerator, unused pens can be used until the expiration date printed on the label.

• If accidentally frozen, the pen must be discarded and should not be used. Please dispose of it properly.

Used Pen:

• After injection, store used pens at room temperature below 30°C.

• Keep away from high temperatures.

• Store pens and needles out of sight and reach of children.

• The pen must be disposed of within 30 days after first use, regardless of whether it has been used up.

• If the full weekly dosage has been completed four times, a new pen should be replaced promptly.

  
  

Registration number

10mg: 1C 43/67 (NC)